Navigation Links
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Date:8/21/2013

ocorticoid-free remission was seen in 31.7 percent and 28.8 percent of patients taking oral glucocorticoids at baseline randomized, respectively, to vedolizumab every eight weeks or every four weeks versus 15.9 percent of patients receiving placebo at week 52 (p=0.02, p=0.04, respectively).

The safety population in GEMINI II comprised 1,115 patients for weeks 0-52. The most common adverse events reported in the 814-patient vedolizumab arm (˃8.0 percent) were Crohn's disease exacerbation, arthralgia, pyrexia, nasopharyngitis, headache, nausea and abdominal pain. The most common adverse events reported in the 301-patient placebo arm (greater than or equal to 8.0 percent) were Crohn's disease exacerbation, headache, arthralgia, pyrexia, abdominal pain, nausea, and nasopharyngitis. Five deaths occurred during the study period, four among patients receiving vedolizumab (one death each from Crohn's disease with sepsis, intentional overdose of prescription medication, myocarditis, and septic shock) and one in the placebo group (from bronchopneumonia).

About the GEMINI™ Studies          
Announced in early 2009, the GEMINI Studies™ is a Phase 3 program evaluating the effect of vedolizumab on clinical response and remission (along with effect on mucosal healing in UC), and long-term safety in moderately to severely active CD and UC patients who had failed at least one conventional therapy or a TNFalpha antagonist. The GEMINI program consists of four separate studies – a placebo-controlled induction and maintenance study in patients with UC (GEMINI I), a placebo-controlled induction and maintenance study in patients with CD (GEMINI II), a placebo-controlled induction study in patients with CD (GEMINI III) and an open-label long-term safety study in patients with either CD or UC (GEMINI LTS).

About Crohn's disease and ulcerative colitis
Crohn's disease (CD) and ul
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
2. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
3. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
4. Depression Study Published on BCM-95 Curcumin
5. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
6. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
7. BioElectronics New Patent Published
8. Benefits of Using Hologics Breast Tomosynthesis Mammography Technology Supported in Published Italian Study
9. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
10. Study Published in European Radiology Further Supports the Use of Hologics Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads
11. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... third international medical cannabis conference taking place at ... France , on October 22, 2014.  The ... stakeholders, such as researchers, health professionals, and patients, ...
(Date:8/22/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the pricing ... stock and warrants at a price of $10,000 per ... deducting underwriting discounts and commissions and offering expenses payable ... separable and will be issued separately.  The shares of ... NASDAQ Stock Market under the ticker symbol "WGBS" on ...
(Date:8/21/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... health, has appointed Holly B. Bauzon as ... Ms. Bauzon has a proven track record in both ... services companies. She has more than 20 years of ... held the position of Director, Lab Services Sales and ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... 22 The American Association of Oral and ... paper on Bisphosphonate-Related Osteonecrosis of the Jaw to ... this condition. BRONJ appears as a non-healing exposed ... patients undergoing intravenous cancer-related bisphosphonate therapy or more ...
... a full service and,leading clinical research organization (CRO), today ... S.r.l., a CRO focused on Phase I to,Phase IV ... http://www.newscom.com/cgi-bin/prnh/20080122/335477 ) , The ... have legal and,operating offices in Milan, Italy. The combined ...
Cached Medicine Technology:AAOMS Updates BRONJ Position Paper 2AAOMS Updates BRONJ Position Paper 3Phidea Srl and Marvin Research Srl Announce Completion of Merger 2Phidea Srl and Marvin Research Srl Announce Completion of Merger 3
(Date:8/22/2014)... This report studies the "Sample Preparation Market ... (Tubes), Kits (Isolation, Purification), By Application (Genomics, Proteomics), ... to 2018" This market was valued at $4,254.8 ... at a CAGR of 5.9% from 2013 to ... Browse 98 market data Tables and 23 Figures ...
(Date:8/22/2014)... With the stage set for the ... Expo - which will be held in Boston August ... in its online opinion section, Podium. The op-ed ... co-authored by Steven C. Anderson, IOM, CAE, president & ... the MCPHS University School of Pharmacy – Worcester/Manchester. ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Millennium Treatment Group ... resulting in a high level of drug use among teenagers. ... fight against drug addiction and work to minimize drug abuse. ... of alcohol and drug addiction in history. According to the ... estimated 23.9 million Americans aged 12 or older—or 9.2 percent ...
(Date:8/22/2014)... Indiana (PRWEB) August 22, 2014 The ... Toyota Indiana is on the grow again. ... 300 jobs by summer 2016 to boost production of ... will bring Toyota Indiana’s overall investment to $4 billion. ... North America while providing additional flexibility to adjust its ...
(Date:8/22/2014)... Medicine team has found that targeted automated alerts ... infections in hospital patients with urinary catheters. In ... simplified, the rate of improvement dramatically increased. , ... need urinary catheters in the first place and ... catheters that have not been removed within a ...
Breaking Medicine News(10 mins):Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3
... 2010 (Portland, Ore.) A new study finds that ... up to a year and the program can also save ... most common eating disorder in the country, affecting more than ... few treatment options are available. But a first-of-a-kind study ...
... upon estrogens to survive and proliferate in about 70% ... treatment to fight this variety of tumours relies on ... of therapy develops in more than 30% of the ... resistance to tamoxifen is thus essential to develop new ...
... ... of Consumers Consider Apples a Value-Based Anytime Food for Both Adults and Children; ,Shoppers ... ... than three-out-of-four Americans, apples and apple beverages fill the dual purpose of being a ...
... gastric cancer patients who have had part or all ... post-operative weight loss and improve appetite, according to a ... of the American Gastroenterological Association (AGA) Institute. "It ... the side effects of gastrectomy. Our study provides convincing ...
... ... , ... 2010 -- Pat Heyward Canes, a new provider of fashion forward walking canes , ... women ranging from classic to whimsical. Made from performance materials, the canes can withstand ...
... ... key management to PCI compliance efforts , ... Salt Lake City, UT (Vocus) March 31, 2010 -- Venafi, ... the security risks they face when encryption keys are not properly monitored and managed., ...
Cached Medicine News:Health News:Short-term program for binge eaters has long-term benefits 2Health News:Short-term program for binge eaters has long-term benefits 3Health News:How breast cancer cells evade therapeutic attacks 2Health News:Apples Are the New Superfruit 2Health News:Apples Are the New Superfruit 3Health News:Apples Are the New Superfruit 4Health News:Promising hormone may help reduce malnutrition in gastric cancer patients 2Health News:Pat Heyward Canes Unveils New Stylish Walking Cane Collection Just in Time for Mother's Day 2Health News:PCI Compliance and Data Security Requires Private Key Management – New Industry White Paper Explains 2
Castroviejo "HM" Micro Needle Holder with Tungsten-Carbide Inserts, with catch. Serrated....
Barraquer needle holder, curved, delicate....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Black finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Medicine Products: